A winter weather advisory is in effect for parts of central Ohio until noon.
HAMILTON, N.Y. (AP) — Colgate defenseman Spiro Goulakos has Hodgkin's lymphoma and has left the team to begin chemotherapy in his native Montreal.
The disease, a type of cancer originating from white blood cells in the lymph nodes, was detected during a routine exam.
Colgate coach Don Vaughan says the news came "as quite a shock to everyone." Vaughan called the past week a very emotional time for the team.
Goulakos is expected to undergo aggressive chemotherapy, given intravenously, over the next four to six months and is expected to fully recover and be back to full academics and athletics at Colgate in the fall.
The disease was discovered during holiday break in December. Goulakos underwent a routine physical examination and one of the lab tests performed returned abnormal results. Additional tests revealed that Goulakos had a large area of swelling in his chest that was not affecting his breathing or his stamina.
More tests were done the day before break ended, and Goulakos also underwent tests with Colgate team physician Dr. Merrill Miller upon his return to school. Those results showed a likely lymphoma in Goulakos' chest.
Miller recommended more sophisticated tests back in Montreal, and Friday morning Goulakos and his family learned the results.
Miller and the doctors in Montreal agreed that since Goulakos was feeling well and his blood counts were normal he could continue playing hockey while awaiting final plans for treatment. Goulakos played in games over the weekend against Brown and Yale but now is out for the rest of the season.
Goulakos was having a terrific sophomore season, with six goals and nine assists in 21 games. He was a major part of the power play for the Raiders as the point man and leader of four rookies on the team's top man-advantage unit that has scored 16 goals. Goulakos is second on the team with four power-play goals.